Arno Bücker

Interventional magnetic resonance. Initial clinical experience with a 1.5-tesla magnetic resonance system combined with c-arm fluoroscopy.

RATIONALE AND OBJECTIVES The authors evaluate the feasibility of performing magnetic resonance (MR) procedures on a 1.5-tesla (T) system combined with conventional c-arm fluoroscopy. METHODS A 1.5-T MR imaging system was combined with a conventional c-arm fluoroscopy unit in one room. The two systems were connected via a floating table top. Twenty-six interventional procedures (biopsies, MR-portography, percutaneous alcohol injection, laser ablation, fluid aspiration, and breast marking) were performed in 22 patients under MR, fluoroscopic control, or both. For MR guidance, fast gradient echo sequences were used, initiated from a panel at the front of the magnet. Images were displayed on an liquid crystal display screen positioned on the magnet. RESULTS All MR-guided procedures were performed successfully without complications. The addition of c-arm fluoroscopy was useful for bone interventions and MR-portography. All diagnostic biopsies yielded sufficient amounts of tissue for histologic diagnosis. In breast lesions, the target identified on dynamic MR imaging was marked correctly in each case. In interstitial laser thermotherapy the laser effect could be visualized, and in percutaneous ethanol injection the distribution of the alcohol could be seen. Both imaging systems worked without image distortions and high-quality MR images were obtained. CONCLUSIONS The combination of a 1.5-T MR imager with a c-arm fluoroscopy system seems to be a promising technical solution for performing interventional MR procedures.

Real-time MR Guidance for Inferior Vena Cava Filter Placement in an Animal Model

It was the aim of this study to examine the feasibility of real-time magnetic resonance (MR) imaging for MR-guided placement of inferior vena cava (IVC) filters, which were placed in five pigs via a femoral approach. The introducer sheath and dilator were marked with Dysprosium rings. The procedures were performed under MR guidance with use of a 1.5-T ACS-NT imager. Radial filling of k-space in conjunction with the sliding window reconstruction technique achieved real-time MR imaging with a frame rate of 20 images/sec. Simultaneous real-time visualization of the vascular anatomy and interventional instruments was achieved under real-time conditions and allowed correct placement of IVC filters in all five cases as confirmed by radiographic angiography.

Comparative in Vitro Study of Two Percutaneous Hydrodynamic Thrombectomy Systems

PURPOSE To test the efficacy of clot removal in small- and large-caliber vessels and determine the extent of procedure-related particle embolization for two rheolytic thrombectomy devices, the Hydrolyser and Angiojet. MATERIALS AND METHODS Both systems were applied with and without guiding catheters in an arterial (7-mm tube diameter, wall-adherent thrombus [mean, 5.3 g], flow of 500 mL/min)and a venous (20-mm tube diameter, free-floating thrombus [mean, 12 g], flow of 1,500 mL/min) flow model. RESULTS Particle embolization was significantly lower for the Angiojet device (mean, 1.8% +/- 2.9 [standard deviation] vs mean 4.8% +/- 6.1 for particles > 1,000 microns). When the devices were used without guiding catheters, mean clot removal rates were 65% +/- 12 with the Hydrolyser and 49% +/- 9.2 with the Angiojet in the arterial flow model and 88% +/- 15.5 with the Hydrolyser and 85% +/- 17.8 with the Angiojet in the venous flow model. Significant improvements in clot removal rates were achieved with use of guiding catheters: 81% +/- 5.4 with the Hydrolyser and 89% +/- 3.9 with the Angiojet in the arterial flow model and 95% +/- 1.4 with the Hydrolyser and 97% +/- 0.84 with the Angiojet in the venous flow model. CONCLUSION Use of guiding catheters improved the performance of both systems significantly. Both rheolytic catheters remove sufficient amounts of soft thrombus from a large-caliber vessel, especially when applied with a guiding catheter. However, firmer thrombus is difficult to remove. The particle embolization rate is low for both systems.

Cine MR imaging of heart valve dysfunction with segmented true fast imaging with steady state free precession.

To evaluate the value of cine true fast imaging with steady‐state free precession (SSFP) for semiquantitative assessment of valvular dysfunction in the heart and to compare the results to that obtained with a standard breath‐hold segmented gradient‐recalled echo‐planar imaging sequence (GE‐EPI).

Magnetic Resonance–Guided Cardiac Interventions Using Magnetic Resonance–Compatible Devices: A Preclinical Study and First-in-Man Congenital Interventions

Background— Percutaneous cardiac interventions are currently performed under x-ray guidance. Magnetic resonance imaging (MRI) has been used to guide intravascular interventions in the past, but mainly in animals. Translation of MR-guided interventions into humans has been limited by the lack of MR-compatible and safe equipment, such as MR guide wires with mechanical characteristics similar to standard guide wires. The aim of the present study was to evaluate the safety and efficacy of a newly developed MR-safe and compatible passive guide wire in aiding MR-guided cardiac interventions in a swine model and describe the 2 first-in-man solely MR-guided interventions. Methods and Results— In the preclinical trial, the new MR-compatible wire aided the performance of 20 interventions in 5 swine. These consisted of balloon dilation of nondiseased pulmonary and aortic valves, aortic arch, and branch pulmonary arteries. After ethics and regulatory authority approval, the 2 first-in-man MR-guided interventions were performed in a child and an adult, both with elements of valvar pulmonary stenosis. Catheter manipulations were monitored with real-time MRI sequence with interactive modification of imaging plane and slice position. Temporal resolution was 11 to 12 frames/s. Catheterization procedure times were 110 and 80 minutes, respectively. Both patients had successful relief of the valvar stenosis and no procedural complications. Conclusions— The described preclinical study and case reports are encouraging that with the availability of the new MR-compatible and safe guide wire, certain percutaneous cardiac interventions will become feasible to perform solely under MR guidance in the future. A clinical trial is underway in our institution.Background—Percutaneous cardiac interventions are currently performed under x-ray guidance. Magnetic resonance imaging (MRI) has been used to guide intravascular interventions in the past, but mainly in animals. Translation of MR-guided interventions into humans has been limited by the lack of MR-compatible and safe equipment, such as MR guide wires with mechanical characteristics similar to standard guide wires. The aim of the present study was to evaluate the safety and efficacy of a newly developed MR-safe and compatible passive guide wire in aiding MR-guided cardiac interventions in a swine model and describe the 2 first-in-man solely MR-guided interventions. Methods and Results—In the preclinical trial, the new MR-compatible wire aided the performance of 20 interventions in 5 swine. These consisted of balloon dilation of nondiseased pulmonary and aortic valves, aortic arch, and branch pulmonary arteries. After ethics and regulatory authority approval, the 2 first-in-man MR-guided interventions were performed in a child and an adult, both with elements of valvar pulmonary stenosis. Catheter manipulations were monitored with real-time MRI sequence with interactive modification of imaging plane and slice position. Temporal resolution was 11 to 12 frames/s. Catheterization procedure times were 110 and 80 minutes, respectively. Both patients had successful relief of the valvar stenosis and no procedural complications. Conclusions—The described preclinical study and case reports are encouraging that with the availability of the new MR-compatible and safe guide wire, certain percutaneous cardiac interventions will become feasible to perform solely under MR guidance in the future. A clinical trial is underway in our institution.

Initial experiences with in vivo intravascular coronary vessel wall imaging

To evaluate potential use of a loopless internal receiver coil for in vivo coronary artery vessel wall imaging in five domestic swine.

Molecular Magnetic Resonance Imaging of Deep Vein Thrombosis Using a Fibrin-targeted Contrast Agent: A Feasibility Study

Purpose:To evaluate the value of a fibrin-specific MR contrast agent (EP-2104R; EPIX Pharmaceuticals) for detection of deep vein thrombosis (DVT) and monitoring of percutaneous intervention for treatment. Materials and Methods:In 6 domestic swine, DVT was induced in an iliac/femoral vein using an occlusion-balloon catheter and subsequent injection of thrombin. The occluded vessels were recanalized by mechanical thrombectomy using a Fogarty catheter and an Arrow rotating thrombectomy device. Magnetic resonance imaging of the pelvis and lung was repeated 4 times (before and after DVT induction, after contrast agent administration, and after intervention) using a 1.5-T whole-body XMR system (ACS-NT, Philips Medical Systems, Best, NL). The visualization of the thrombi and contrast-to-noise ratio (CNR) was assessed. Results:EP-2104R allowed selective visualization of thrombi with accurate determination of the extent of DVT with high contrast (CNR: 65.3 ± 17.2). After intervention, dislodged thrombus fragments were selectively visualized in the lung (CNR: 27.9 ± 9.3). Conclusions:Molecular magnetic resonance imaging using fibrin-specific MR contrast agent EP-2104R allowed for selective visualization of DVT and monitoring of percutaneous intervention.

Contrast-enhanced magnetic resonance urography. First experimental results with a polymeric gadolinium bloodpool agent.

RATIONALE AND OBJECTIVES The authors investigated the feasibility of contrast-enhanced excretory magnetic resonance urography to visualize the nonobstructed urinary tract with a macromolecular gadolinium-based bloodpool agent. METHODS Excretory magnetic resonance imaging was performed in seven pigs using a T1-weighted three dimensional fast-field-echo sequence before and up to 120 minutes after administration of a gadolinium bloodpool prototype agent. RESULTS During the first 15 minutes after injection, the urographic effect was predominantly poor. Visualization of the entire urinary tract was excellent in four pigs and incomplete but satisfactory in three 105 minutes after injection. Furosemide application was tested in one case, which improved image quality effectively. Corresponding to the physiological excretion rate, signal measurements in the renal parenchyma revealed a gradual decrease of the initially distinct contrast enhancement. CONCLUSIONS T1-weighted contrast-enhanced magnetic resonance urography using a polymeric gadolinium bloodpool allows detailed visualization of the normal urinary tract, while information about the excretory function is obtained simultaneously. However, application of a diuretic seems to be essential to prevent lengthy examination duration.

Magnetic Resonance–Guided Cardiac Interventions Using Magnetic Resonance–Compatible DevicesClinical Perspective

Background— Percutaneous cardiac interventions are currently performed under x-ray guidance. Magnetic resonance imaging (MRI) has been used to guide intravascular interventions in the past, but mainly in animals. Translation of MR-guided interventions into humans has been limited by the lack of MR-compatible and safe equipment, such as MR guide wires with mechanical characteristics similar to standard guide wires. The aim of the present study was to evaluate the safety and efficacy of a newly developed MR-safe and compatible passive guide wire in aiding MR-guided cardiac interventions in a swine model and describe the 2 first-in-man solely MR-guided interventions. Methods and Results— In the preclinical trial, the new MR-compatible wire aided the performance of 20 interventions in 5 swine. These consisted of balloon dilation of nondiseased pulmonary and aortic valves, aortic arch, and branch pulmonary arteries. After ethics and regulatory authority approval, the 2 first-in-man MR-guided interventions were performed in a child and an adult, both with elements of valvar pulmonary stenosis. Catheter manipulations were monitored with real-time MRI sequence with interactive modification of imaging plane and slice position. Temporal resolution was 11 to 12 frames/s. Catheterization procedure times were 110 and 80 minutes, respectively. Both patients had successful relief of the valvar stenosis and no procedural complications. Conclusions— The described preclinical study and case reports are encouraging that with the availability of the new MR-compatible and safe guide wire, certain percutaneous cardiac interventions will become feasible to perform solely under MR guidance in the future. A clinical trial is underway in our institution.Background—Percutaneous cardiac interventions are currently performed under x-ray guidance. Magnetic resonance imaging (MRI) has been used to guide intravascular interventions in the past, but mainly in animals. Translation of MR-guided interventions into humans has been limited by the lack of MR-compatible and safe equipment, such as MR guide wires with mechanical characteristics similar to standard guide wires. The aim of the present study was to evaluate the safety and efficacy of a newly developed MR-safe and compatible passive guide wire in aiding MR-guided cardiac interventions in a swine model and describe the 2 first-in-man solely MR-guided interventions. Methods and Results—In the preclinical trial, the new MR-compatible wire aided the performance of 20 interventions in 5 swine. These consisted of balloon dilation of nondiseased pulmonary and aortic valves, aortic arch, and branch pulmonary arteries. After ethics and regulatory authority approval, the 2 first-in-man MR-guided interventions were performed in a child and an adult, both with elements of valvar pulmonary stenosis. Catheter manipulations were monitored with real-time MRI sequence with interactive modification of imaging plane and slice position. Temporal resolution was 11 to 12 frames/s. Catheterization procedure times were 110 and 80 minutes, respectively. Both patients had successful relief of the valvar stenosis and no procedural complications. Conclusions—The described preclinical study and case reports are encouraging that with the availability of the new MR-compatible and safe guide wire, certain percutaneous cardiac interventions will become feasible to perform solely under MR guidance in the future. A clinical trial is underway in our institution.

Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.

Objectives:The aim of this study was to evaluate lesion enhancement (LE) and contrast-to-noise ratio (CNR) properties of P846, a new intermediate sized, high relaxivity Gd-based contrast agent at 3 Tesla in a rat brain glioma model, and to compare this contrast agent with a high relaxivity, macromolecular compound (P792), and a standard extracellular Gd-chelate (Gd-DOTA). Materials and Methods:Seven rats with experimental induced brain glioma were evaluated using 3 different contrast agents, with each MR examination separated by at least 24 hours. The time between injections assured sufficient clearance of the agent from the tumor, before the next examination. P792 (Gadomelitol, Guerbet, France) and P846 (a new compound from Guerbet Research) are macromolecular and high relaxivity contrast agents with no protein binding, and were compared with the extracellular agent Gd-DOTA (Dotarem, Guerbet, France). T1w gradient echo sequences (TR/TE 200 milliseconds/7.38 milliseconds, flip angle = 90°, acquisition time: 1:42 minutes:sec, voxel size: 0.2 × 0.2 × 2.0 mm3, FOV = 40 mm, acquisition matrix: 256 × 256) were acquired before and at 5 consecutive time points after each intravenous contrast injection in the identical slice orientation, using a dedicated 4-channel head array animal coil. The order of contrast media injection was randomized, with however Gd-DOTA used either as the first or second contrast agent. Contrast agent dose was adjusted to compensate for the different T1 relaxivities of the 3 agents. Signal-to-noise ratio, CNR, and LE were evaluated using region-of-interest analysis. A veterinary histopathologist confirmed the presence of a glioma in each subject, after completion of the imaging study. Results:P792 showed significantly less LE as compared with Gd-DOTA within the first 7 minutes after contrast agent injection (P < 0.05) with, however, reaching comparable LE values at 9 minutes after injection (P = 0.07). However, P792 provided significantly less CNR as compared with Gd-DOTA (P < 0.05) for all examination time points. P846 provided comparable but persistent LE as compared with Gd-DOTA (P < 0.05) and demonstrated significantly greater LE and CNR when compared with P792 (P < 0.05). No statistically significant differences between CNR values for Gd-DOTA and P846 were noted for all examination time points (P < 0.05), with P846 administered at one-fourth the dose as compared with Gd-DOTA. Conclusion:The intravascular contrast medium P792 showed significantly less LE and CNR in comparison to Gd-DOTA and P846, suggesting that it does not show marked extravasation from tumor neocapillaries and does not significantly cross the disrupted blood brain-barrier in this rat glioma model. In distinction, P846 provides comparable enhancement properties at a field strength of 3 Tesla to the extracellular contrast agent Gd-DOTA, using the adjusted dose, suggesting that it crosses the disrupted blood-brain-barrier and tumor capillaries, most likely based on the decreased molecular weight as compared with P792. At the same time, the high relaxivity of this compound allows for decreasing the injected gadolinium dose by a factor of 4 whereas providing comparable enhancement properties when compared with a standard extracellular Gd-chelate (Gd-DOTA) at a dose of 0.1 mmol/kg body weight.